Genmab — Juli 2017
-
God morgen.

-
Lang tid siden med et regulært insiderkøb.
-
Blandt de mange nye studier ser dette egentlig lidt interessant ud: https://clinicaltrials.gov/ct2/show/NCT03068351?term=daratumumab+roche&rank=2
-
-
Fred være med det Mogan. "Fald" er en naturlig del af aktiemarkedet.
-
Det bestemmer Anonyme.

-
Helge: Igen enig. Fald er naturligt, og giver mulighed for opkøb. Casen er intakt. Jeg er lang i GEN, og reagerer ikke på baggrund af følelser. Sælger ikke da jeg ikke tror på, at jeg kan ramme top/bund ved udsvingene. De evt. mere spekulative køb/salg transaktioner
kan jeg alligevel ikke hamle op med:-) -
Q&A med CEO Britt Meelbye Jensen fra Zealand Pharma starter om få minutter.
-
se pkt 4 - her er lidt flavor på markedsstørrelse - http://www.regioner.dk/media/5214/dara-mini-mtv-bor-dex.pdf
-
og så kommer dara+len+dex oven i hatten, men jeg kan ikke lige finde KRIS dokumentaet på castor comboen
-
U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its Keytruda in combination with other medicines for the blood cancer after more deaths were reported in patients receiving the Merck immunotherapy.
https://finance.yahoo.com/news/fda-puts-hold-merck-multiple-213905828.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind